Conditions
Bladder Cancer, High-risk Non-muscle Invasive Bladder Cancer
Trial Purpose
Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment.
The goals of this study are to learn: 1. If more people who receive pembrolizumab with Bacillus Calmette-Guerin (BCG) have no signs of cancer in their body and live longer without the cancer growing, spreading, or coming back compared to people who receive BCG alone. 2. About the safety and how well people tolerate BCG alone or in combination with pembrolizumab.
NATIONAL TRIAL REFERENCE NUMBER
NCT03711032
EudraCT
2018-001967-22
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
Resources
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
18+
Sex
All
About The Trial
All patients who enrol in the trial will receive medication while on the study.Cohort A: All patients who enroll in the trial will receive medication while on the study.
50% of participants will receive BCG+Pembrolizumab
50% of participants will receive BCG only
Cohort B: All patients who enroll in the trial will receive medication while on the study.
33% of participants will receive Pembrolizumab and BCG (reduced BCG course)
33% of participants will receive Pembrolizumab and BCG (full BCG course)
33% of participants will receive BCG alone (full BCG course)
Trial Phase
Trial Phase 3
Tests the medicine or vaccine in large groups of trial participants (from several hundred to several thousand). For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or doctors’ offices.
Trial start and end dates
- Actual study start date 24 December 2018
- Estimated primary completion date 31 December 2025
- Estimated study completion date 12 October 2028
Trial locations
Sorry, there are no locations found.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
Taking part in a clinical trial is an important decision
If you are considering joining a clinical trial, first learn as much as you can about:
- The investigational treatment that is being studied
- What the risks and possible benefits are for participants
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about